Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: apriluv who wrote (1851)	4/15/2016 6:58:42 PM
From: mokelumne river	Respond to of 2026

Makes sense as there is not much for Dr. Troupin to do. Doesn't appear that the company will accrue savings from her departure in 2016. This from the 8K: >On April 13, 2016, Apricus Biosciences, Inc. (the "Company") entered into an Employment Transition Agreement with Barbara Troupin, M.D., M.B.A., the Company's Senior Vice President, Chief Medical Officer. Pursuant to the agreement, Dr. Troupin's employment with the Company will terminate effective as of May 31, 2016. Dr. Troupin intends to pursue other opportunities in light of the Company's decision to deprioritize its pipeline assets and focus on the commercialization of Vitaros. Pursuant to the agreement, following her termination of employment and subject to her execution of a general release of claims, Dr. Troupin will be entitled to receive certain severance benefits, including the payment of her annual base salary, an amount equal to her annual bonus for 2015, six months of continued health benefits at Company expense, and full acceleration of all of her outstanding equity awards.<